Vericel (NASDAQ:VCEL) Upgraded at StockNews.com

StockNews.com upgraded shares of Vericel (NASDAQ:VCEL) from a sell rating to a hold rating in a research note published on Friday.

Other analysts have also recently issued reports about the company. Canaccord Genuity Group assumed coverage on Vericel in a research report on Friday, August 9th. They set a “buy” rating and a $57.00 price target on the stock. Canaccord Genuity Group assumed coverage on Vericel in a report on Friday, August 9th. They issued a “buy” rating and a $57.00 price objective for the company. BTIG Research decreased their price objective on Vericel from $56.00 to $55.00 and set a “buy” rating for the company in a report on Monday, July 15th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Vericel in a report on Friday. Finally, Truist Financial increased their price target on Vericel from $56.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $57.71.

Vericel Stock Up 7.9 %

Shares of NASDAQ VCEL opened at $54.00 on Friday. The stock’s 50 day moving average price is $44.27 and its two-hundred day moving average price is $46.40. Vericel has a 52-week low of $32.28 and a 52-week high of $54.47. The stock has a market capitalization of $2.65 billion, a P/E ratio of -5,400,000.00 and a beta of 1.66.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.03. Vericel had a return on equity of 0.35% and a net margin of 0.37%. The firm had revenue of $57.91 million for the quarter, compared to analysts’ expectations of $55.32 million. On average, analysts anticipate that Vericel will post 0.12 EPS for the current year.

Insider Activity

In other news, Director Steven C. Gilman sold 5,833 shares of the stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $41.36, for a total value of $241,252.88. Following the completion of the sale, the director now owns 11,000 shares in the company, valued at $454,960. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Steven C. Gilman sold 5,833 shares of the stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $41.36, for a total transaction of $241,252.88. Following the completion of the sale, the director now directly owns 11,000 shares in the company, valued at approximately $454,960. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total value of $724,150.00. Following the sale, the chief executive officer now owns 220,937 shares of the company’s stock, valued at approximately $9,142,373.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,166 shares of company stock worth $1,200,764 over the last quarter. Corporate insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Vericel

Several hedge funds have recently bought and sold shares of the business. Intech Investment Management LLC acquired a new stake in shares of Vericel in the third quarter valued at about $563,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in Vericel by 4.6% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,079,048 shares of the biotechnology company’s stock worth $45,590,000 after buying an additional 47,108 shares in the last quarter. Moran Wealth Management LLC grew its position in Vericel by 42.4% during the third quarter. Moran Wealth Management LLC now owns 10,755 shares of the biotechnology company’s stock worth $454,000 after buying an additional 3,204 shares in the last quarter. Advisors Asset Management Inc. grew its position in Vericel by 4.0% during the third quarter. Advisors Asset Management Inc. now owns 16,890 shares of the biotechnology company’s stock worth $714,000 after buying an additional 644 shares in the last quarter. Finally, Global Alpha Capital Management Ltd. grew its position in Vericel by 60.2% during the third quarter. Global Alpha Capital Management Ltd. now owns 23,383 shares of the biotechnology company’s stock worth $988,000 after buying an additional 8,791 shares in the last quarter.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.